175 results on '"Botros, M"'
Search Results
152. From the first selective non-peptide AT(2) receptor agonist to structurally related antagonists.
- Author
-
Murugaiah AM, Wu X, Wallinder C, Mahalingam AK, Wan Y, Sköld C, Botros M, Guimond MO, Joshi A, Nyberg F, Gallo-Payet N, Hallberg A, and Alterman M
- Subjects
- Angiotensin II Type 2 Receptor Blockers chemistry, Angiotensin II Type 2 Receptor Blockers pharmacology, Animals, Carbamates chemistry, Carbamates pharmacology, Female, Imidazoles chemistry, Imidazoles pharmacology, In Vitro Techniques, Liver metabolism, Myometrium metabolism, Radioligand Assay, Rats, Receptor, Angiotensin, Type 2 agonists, Structure-Activity Relationship, Sulfonamides chemistry, Sulfonamides pharmacology, Swine, Thiophenes chemistry, Thiophenes pharmacology, Angiotensin II Type 2 Receptor Blockers chemical synthesis, Carbamates chemical synthesis, Imidazoles chemical synthesis, Receptor, Angiotensin, Type 2 metabolism, Sulfonamides chemical synthesis, Thiophenes chemical synthesis
- Abstract
A para substitution pattern of the phenyl ring is a characteristic feature of the first reported selective AT(2) receptor agonist M024/C21 (1) and all the nonpeptidic AT(2) receptor agonists described so far. Two series of compounds structurally related to 1 but with a meta substitution pattern have now been synthesized and biologically evaluated for their affinity to the AT(1) and AT(2) receptors. A high AT(2)/AT(1) receptor selectivity was obtained with all 41 compounds synthesized, and the majority exhibited K(i) ranging from 2 to 100 nM. Five compounds were evaluated for their functional activity at the AT(2) receptor, applying a neurite outgrowth assay in NG108-15 cells. Notably, four of the five compounds, with representatives from both series, acted as potent AT(2) receptor antagonists. These compounds were found to be considerably more effective than PD 123,319, the standard AT(2) receptor antagonist used in most laboratories. No AT(2) receptor antagonists were previously reported among the derivatives with a para substitution pattern. Hence, by a minor modification of the agonist 1 it could be transformed into the antagonist, compound 38. These compounds should serve as valuable tools in the assessment of the role of the AT(2) receptor in more complex physiological models.
- Published
- 2012
- Full Text
- View/download PDF
153. Recurrent invasive lobular carcinoma presenting as a ruptured breast implant.
- Author
-
Botros M, Chang K, Miller R, Krishnan S, and Iott M
- Abstract
Background: For years, the treatment for invasive lobular carcinoma (ILC) has been mastectomy secondary to the lack of studies investigating the efficacy of breast conservation therapy on patients afflicted with ILC and due to the lack of long-term follow up investigating locoregional recurrence in this patient population. In this article we report the clinical course of a patient diagnosed with ILC., Case Report: We describe the case of a 50-year-old woman with stage IIB (T2N1M0) ER/PR positive right breast ILC who underwent a right modified radical mastectomy, postoperative chemotherapy, a prophylactic left simple mastectomy with bilateral breast reconstruction and tamoxifen. Approximately 12 years later, she presented with a deflated breast implant and recurrent breast cancer with metastatic spread. She received palliative radiotherapy then palliative chemotherapy. Unfortunately, she succumbed to the cancer less than a year after being diagnosed with metastatic disease., Conclusions: This may be the first case report of a ruptured breast implant presenting at the same time as the diagnosis of recurrent breast cancer.
- Published
- 2012
- Full Text
- View/download PDF
154. Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy.
- Author
-
Hallemeier CL, Botros M, Corsini MM, Haddock MG, Gunderson LL, and Miller RC
- Subjects
- Adenocarcinoma mortality, Adenocarcinoma therapy, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor blood, Chemotherapy, Adjuvant, Combined Modality Therapy, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Pancreatectomy, Pancreatic Neoplasms mortality, Pancreatic Neoplasms therapy, Preoperative Period, Prognosis, Proportional Hazards Models, Radiotherapy, Adjuvant, Retrospective Studies, Survival Analysis, Adenocarcinoma blood, Biomarkers, Tumor analysis, CA-19-9 Antigen blood, Pancreatic Neoplasms blood
- Abstract
Objectives: To evaluate preoperative CA 19-9 level as a prognostic factor in patients with resected adenocarcinoma of the pancreas., Methods: We retrospectively reviewed the cases of consecutive patients with pancreatic adenocarcinoma who had CA 19-9 measured preoperatively and underwent potentially curative resection at Mayo Clinic from September 1995 to January 2005. Patients who died within 30 days of resection were excluded., Results: Search of our database identified 226 consecutive patients who met all the inclusion criteria. Adjuvant therapy was concurrent chemoradiotherapy (CCRT) in 122 patients, CCRT followed by chemotherapy in 23 patients, chemotherapy alone in 6 patients, and none in 69 patients. Median follow-up for surviving patients was 2.1 years. Median survival in all patients was 1.6 years. Patients with a high preoperative CA 19-9 level (defined as ≥180 U/mL) had a greater chance of having pathologic T3-T4 disease (P=0.03), positive lymph nodes (P=0.01), and histologic grade 3 or 4 (P=0.02). In multivariate analysis, a high preoperative CA 19-9 level (P=0.006) and R1-R2 margin status (P=0.03) were associated with decreased survival. Overall survival was increased for patients who received adjuvant CCRT (vs. those who did not; P=0.002) and for patients with high preoperative CA 19-9 level who received adjuvant CCRT (vs. those who did not; P<0.001)., Conclusions: In patients with resected adenocarcinoma of the pancreas, high preoperative CA 19-9 level was associated with adverse pathologic features and poorer survival. Adjuvant CCRT was associated with a significant survival benefit in patients with high preoperative CA 19-9 but not in those with low CA 19-9.
- Published
- 2011
- Full Text
- View/download PDF
155. Radiotherapy for marginally resected, unresectable or recurrent giant cell tumor of the bone: a rare cancer network study.
- Author
-
Bhatia S, Miszczyk L, Roelandts M, Nguyen TD, Boterberg T, Poortmans P, Vallow L, Dincbas FO, Lassen-Ramshad Y, Botros M, and Miller RC
- Abstract
The role of radiotherapy for local control of marginally resected, unresectable, and recurrent giant cell tumors of bone (GCToB) has not been well defined. The number of patients affected by this rare disease is low. We present a series of 58 patients with biopsy proven GCToB who were treated with radiation therapy. A retrospective review of the role of radiotherapy in the treatment of GCToB was conducted in participating institutions of the Rare Cancer Network. Eligibility criteria consisted of the use of radiotherapy for marginally resected, unresectable, and recurrent GCToB. Fifty-eight patients with biopsy proven GCToB were analyzed from 9 participating North American and European institutions. Forty-five patients had a primary tumor and 13 patients had a recurrent tumor. Median radiation dose was 50 Gy in a median of 25 fractions. Indication for radiation therapy was marginal resection in 33 patients, unresectable tumor in 13 patients, recurrence in 9 patients and palliation in 2 patients. Median tumor size was 7.0 cm. A significant proportion of the tumors involved critical structures. Median follow-up was 8.0 years. Five year local control was 85% . Of the 7 local failures, 3 were treated successfully with salvage surgery. All patients who received palliation achieved symptom relief. Five year overall survival was 94%. None of the patients experienced grade 3 or higher acute toxicity. This study reports a large published experience in the treatment of GCToB with radiotherapy. Radiotherapy can provide excellent local control for incompletely resected, unresectable or recurrent GCToB with acceptable morbidity.
- Published
- 2011
- Full Text
- View/download PDF
156. Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.
- Author
-
Mahalingam AK, Wan Y, Murugaiah AM, Wallinder C, Wu X, Plouffe B, Botros M, Nyberg F, Hallberg A, Gallo-Payet N, and Alterman M
- Subjects
- Animals, Cytochrome P-450 Enzyme System metabolism, Heterocyclic Compounds chemical synthesis, Heterocyclic Compounds chemistry, Heterocyclic Compounds pharmacology, Hybrid Cells, Imidazoles chemistry, Mice, Neurites metabolism, Protein Binding, Rats, Receptor, Angiotensin, Type 2 metabolism, Structure-Activity Relationship, Sulfonamides chemical synthesis, Sulfonamides pharmacology, Thiophenes chemical synthesis, Thiophenes pharmacology, Cytochrome P-450 Enzyme Inhibitors, Receptor, Angiotensin, Type 2 agonists, Sulfonamides chemistry, Thiophenes chemistry
- Abstract
Structural alterations to the benzylic position of the first drug-like selective angiotensin II AT(2) receptor agonist (1) have been performed, with the emphasis to reduce the CYP 450 inhibitory property of the initial structure. The imidazole moiety, responsible for the CYP 450 inhibitory effect in 1, was replaced with various heterocycles. In addition, the modes of attachment of the heterocycles, that is, carbon versus nitrogen attachment, and introduction of carbonyl functionalities to the benzylic position have been evaluated. In all the three series, AT(2) receptor ligands with affinity in the lower nanomolar range were identified. None of the analogues, regardless of the substituents, exhibited any affinity for the AT(1) receptor. Compounds with substantially reduced inhibition of the CYP 450 enzymes were obtained. Among them the compound 60 was found to induce neurite elongation in NG 108-15 cells and served as potent AT(2) selective agonist., (Copyright 2010 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
157. Discovery of dipeptides with high affinity to the specific binding site for substance P1-7.
- Author
-
Fransson R, Botros M, Sköld C, Nyberg F, Lindeberg G, Hallberg M, and Sandström A
- Subjects
- Amino Acid Sequence, Animals, Binding Sites, Binding, Competitive, Dipeptides chemical synthesis, Drug Discovery, Humans, Kinetics, Male, Molecular Structure, Peptide Fragments chemistry, Protein Binding, Radioligand Assay, Rats, Rats, Sprague-Dawley, Receptors, Neurokinin-1 metabolism, Receptors, Neurokinin-3 metabolism, Spinal Cord metabolism, Substance P chemistry, Dipeptides chemistry, Dipeptides metabolism, Peptide Fragments metabolism, Substance P metabolism
- Abstract
Substance P 1-7 (SP(1-7), H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-OH) is the major bioactive metabolite of substance P. The interest in this heptapeptide originates from the observation that it modulates, and in certain cases opposes the effects of the parent peptide, e.g., the nociceptive effect. The mu-opioid receptor agonist endomorphin-2 (EM-2, H-Tyr-Pro-Phe-Phe-NH(2)) has been found to also interact with the specific binding site of SP(1-7) with only a 10-fold lower affinity compared to the native peptide. Considering the smaller size of EM-2 compared to the target heptapeptide, it was selected as a lead compound in the development of low-molecular-weight ligands to the SP(1-7) binding site. An alanine scan and truncation study led to the unexpected discovery of the dipeptide H-Phe-Phe-NH(2) (K(i) = 1.5 nM), having equal affinity as the endogenous heptapeptide SP(1-7.) Moreover, the studies show that the C-terminal phenylalanine amide is crucial for the affinity of the dipeptide.
- Published
- 2010
- Full Text
- View/download PDF
158. The C-terminal amidated analogue of the substance P (SP) fragment SP(1-7) attenuates the expression of naloxone-precipitated withdrawal in morphine dependent rats.
- Author
-
Zhou Q, Carlsson A, Botros M, Fransson R, Sandström A, Gordh T, Hallberg M, and Nyberg F
- Subjects
- Animals, Antipsychotic Agents pharmacology, Antipsychotic Agents therapeutic use, Brain drug effects, Brain metabolism, Male, Peptide Fragments metabolism, Phenazocine analogs & derivatives, Phenazocine pharmacology, Rats, Rats, Wistar, Substance P pharmacology, Morphine Dependence physiopathology, Naloxone therapeutic use, Peptide Fragments chemistry, Peptide Fragments pharmacology, Substance P chemistry, Substance Withdrawal Syndrome physiopathology
- Abstract
We previously demonstrated that intracerebroventricular (i.c.v.) administration of the substance P (SP) aminoterminal fragment SP(1-7) attenuates the expression of morphine withdrawal in the male rat. In this study we have used a synthetic analogue of this peptide, i.e. the SP(1-7) amide showing higher binding potency than the native heptapeptide, in a similar experimental set-up. Thus, Wistar male rats were made tolerant to morphine by daily injections of the opiate during 8 days. Following peptide administration (i.c.v.) and a subsequent naloxone challenge a variety of physical syndromes of withdrawal were recorded. We observed that the SP(1-7) amide potently and dose-dependently reduced several signs of reaction to morphine withdrawal. Interestingly, the effect of the peptide amide was significantly attenuated by the addition of the sigma agonist (+)-SKF-10047. We conclude that the SP(1-7) amide mimics the effect of the native SP fragment and that the mechanisms for its action involve a sigma receptor site.
- Published
- 2009
- Full Text
- View/download PDF
159. Endomorphins interact with the substance P (SP) aminoterminal SP(1-7) binding in the ventral tegmental area of the rat brain.
- Author
-
Botros M, Johansson T, Zhou Q, Lindeberg G, Tömböly C, Tóth G, Le Grevès P, Nyberg F, and Hallberg M
- Subjects
- Animals, Binding Sites, Male, Protein Binding, Rats, Rats, Sprague-Dawley, Ventral Tegmental Area chemistry, Ventral Tegmental Area cytology, Analgesics, Opioid metabolism, Oligopeptides metabolism, Peptide Fragments metabolism, Substance P metabolism, Ventral Tegmental Area metabolism
- Abstract
We have recently identified a specific binding site for the tachykinin peptide substance P (SP) fragment SP(1-7) in the rat spinal cord. This site appeared very specific for SP(1-7) as the binding affinity of this compound highly exceeded those of other SP fragments. We also observed that endomorphin-2 (EM-2) exhibited high potency in displacing SP(1-7) from this site. In the present work using a [(3)H]-labeled derivative of the heptapeptide we have identified and characterized [(3)H]-SP(1-7) binding in the rat ventral tegmental area (VTA). Similarly to the [(3)H]-SP(1-7) binding in the spinal cord the affinity of unlabeled SP(1-7) to the specific site in VTA was significantly higher than those of other SP fragments. Further, the tachykinin receptor NK-1, NK-2 and NK-3 ligands showed no or negligible binding to the identified site. However, the mu-opioid peptide (MOP) receptor agonists DAMGO, EM-1 and EM-2 did, and significant difference was observed in the binding affinity between the two endomorphins. As recorded from displacement curves the affinity of EM-2 for the SP(1-7) site was 4-5 times weaker than that for SP(1-7) but about 5 times higher than that of EM-1. The opioid receptor antagonists naloxone and naloxonazine showed weak or negligible binding. It was concluded that the specific site identified for SP(1-7) binding in the rat VTA is distinct from the MOP receptor although it exhibits high affinity for EM-2.
- Published
- 2008
- Full Text
- View/download PDF
160. Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships.
- Author
-
Wallinder C, Botros M, Rosenström U, Guimond MO, Beaudry H, Nyberg F, Gallo-Payet N, Hallberg A, and Alterman M
- Subjects
- Cell Line, Humans, Neurites drug effects, Structure-Activity Relationship, Benzamides chemistry, Benzamides pharmacology, Receptor, Angiotensin, Type 2 agonists
- Abstract
In the investigation of the structure-activity relationship of nonpeptide AT(2) receptor agonists, a series of substituted benzamide analogues of the selective nonpeptide AT(2) receptor agonist M024 have been synthesised. In a second series, the biphenyl scaffold was compared to the thienylphenyl scaffold and the impact of the isobutyl substituent and its position on AT(1)/AT(2) receptor selectivity was also investigated. Both series included several compounds with high affinity and selectivity for the AT(2) receptor. Three of the compounds were also proven to function as agonists at the AT(2) receptor, as deduced from a neurite outgrowth assay, conducted in NG108-15 cells.
- Published
- 2008
- Full Text
- View/download PDF
161. Small peptides mimicking substance P (1-7) and encompassing a C-terminal amide functionality.
- Author
-
Fransson R, Botros M, Nyberg F, Lindeberg G, Sandström A, and Hallberg M
- Subjects
- Amides chemistry, Animals, Chromatography, High Pressure Liquid, In Vitro Techniques, Ligands, Male, Mass Spectrometry, Membranes metabolism, Molecular Mimicry, Peptide Fragments chemical synthesis, Peptide Fragments metabolism, Radioligand Assay, Rats, Rats, Sprague-Dawley, Spectrophotometry, Ultraviolet, Spinal Cord metabolism, Structure-Activity Relationship, Substance P chemical synthesis, Substance P metabolism, Peptide Fragments pharmacology, Substance P pharmacology
- Abstract
Some of the biological effects demonstrated after administration of substance P (SP) in vivo can indirectly be attributed to the fragmentation of the undecapeptide to its N-terminal bioactive fragment SP(1-7). This heptapeptide (H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-OH) is a major bioactive metabolite from SP that frequently exerts similar biological effects as the parent peptide but also, in several cases, completely opposite actions. Specific binding sites for the heptapeptide SP(1-7) that are separate from the SP preferred NK receptors have been identified. In this study we demonstrate that (a) the C-terminal part of the SP metabolite SP(1-7) is most important for binding as deduced from an Ala scan and that a replacement of Phe(7) for Ala is deleterious, (b) truncation of the N-terminal amino acid residues of SP(1-7) delivers peptides with retained binding activity, although with somewhat lower binding affinities than SP(1-7) and (c) a C-terminal amide group as a replacement for the terminal carboxy group of SP(1-7) and for all of the truncated ligands synthesized affords approximately 5-10-fold improvements of the binding affinities.
- Published
- 2008
- Full Text
- View/download PDF
162. Selective angiotensin II AT(2) receptor agonists devoid of the imidazole ring system.
- Author
-
Murugaiah AM, Wallinder C, Mahalingam AK, Wu X, Wan Y, Plouffe B, Botros M, Karlén A, Hallberg M, Gallo-Payet N, and Alterman M
- Subjects
- Animals, Binding Sites, Cell Differentiation drug effects, Cell Line, Tumor, Cell Membrane chemistry, Female, Humans, Imidazoles chemical synthesis, Imidazoles chemistry, In Vitro Techniques, Ligands, Molecular Structure, Myometrium chemistry, Stereoisomerism, Structure-Activity Relationship, Swine, Imidazoles pharmacology, Receptor, Angiotensin, Type 2 agonists
- Abstract
A versatile parallel synthetic method to obtain three series of non-cyclic analogues of the first drug-like selective angiotensin II AT(2) receptor agonist (1) has been developed. In analogy with the transformation of losartan to valsartan it was demonstrated that a non-cyclic moiety could be employed as an imidazole replacement to obtain AT(2) selective compounds. In all the three series, AT(2) receptor ligands with affinities in the lower nanomolar range were found. None of the analogues exhibited any affinity for the AT(1) receptor. Four compounds, 17, 22, 39 and 51, were examined in a neurite outgrowth cell assay. All four compounds were found to exert a high agonistic effect as deduced from their capacity to induce neurite elongation in neuronal cells, as does angiotensin II.
- Published
- 2007
- Full Text
- View/download PDF
163. Synthesis of a new class of druglike angiotensin II C-terminal mimics with affinity for the AT2 receptor.
- Author
-
Georgsson J, Sköld C, Botros M, Lindeberg G, Nyberg F, Karlén A, Hallberg A, and Larhed M
- Subjects
- Animals, Female, In Vitro Techniques, Ligands, Liver metabolism, Models, Molecular, Molecular Mimicry, Myometrium metabolism, Oligopeptides chemistry, Oligopeptides pharmacology, Radioligand Assay, Rats, Structure-Activity Relationship, Swine, Angiotensin II chemistry, Oligopeptides chemical synthesis, Receptor, Angiotensin, Type 2 agonists
- Abstract
Four tripeptides corresponding to the C-terminal region of angiotensin II were synthesized. One of these peptides (Ac-His-Pro-Ile) showed moderate binding affinity for the AT2 receptor. Two aromatic histidine-related scaffolds were synthesized and introduced in the tripeptides to give eight new peptidomimetic structures. Three of the new peptide-derived druglike molecules exhibited selective, nanomolar affinity for the AT2 receptor. These ligands may become lead compounds in the future development of novel classes of selective AT2 receptor agonists.
- Published
- 2007
- Full Text
- View/download PDF
164. Selective angiotensin II AT2 receptor agonists: arylbenzylimidazole structure-activity relationships.
- Author
-
Wu X, Wan Y, Mahalingam AK, Murugaiah AM, Plouffe B, Botros M, Karlén A, Hallberg M, Gallo-Payet N, and Alterman M
- Subjects
- Animals, Benzimidazoles chemistry, Benzimidazoles pharmacology, Cell Differentiation drug effects, Cell Line, Tumor, Female, Ligands, Liver metabolism, Neurites drug effects, Neurites physiology, Radioligand Assay, Rats, Structure-Activity Relationship, Sulfonamides chemistry, Sulfonamides pharmacology, Swine, Thiophenes chemistry, Thiophenes pharmacology, Uterus metabolism, Benzimidazoles chemical synthesis, Receptor, Angiotensin, Type 2 agonists, Sulfonamides chemical synthesis, Thiophenes chemical synthesis
- Abstract
Structural alterations in the 2- and 5-positions of the first drug-like selective angiotensin II AT2 receptor agonist (1) have been performed. The imidazole ring system was proven to be a strong determinant for the AT2 selectivity, and with few exceptions all variations gave good AT2 receptor affinities and with retained high AT2/AT1 selectivities. On the contrary to the findings with AT1 receptor agonists, the impact of structural modifications in the 5-position of the AT2 selective compounds were less pronounced regarding activation of the AT2 receptor. The butyloxyphenyl (56) and the propylthienyl (50) derivatives were found to exert a high agonistic effect as deduced from their capacity to induce neurite elongation in neuronal cells, as does angiotensin II.
- Published
- 2006
- Full Text
- View/download PDF
165. Design, synthesis, and incorporation of a beta-turn mimetic in angiotensin II forming novel pseudopeptides with affinity for AT1 and AT2 receptors.
- Author
-
Rosenström U, Sköld C, Lindeberg G, Botros M, Nyberg F, Karlén A, and Hallberg A
- Subjects
- Animals, Aorta, Thoracic drug effects, Aorta, Thoracic physiology, Benzodiazepines chemistry, Benzodiazepines pharmacology, Drug Design, Female, In Vitro Techniques, Ligands, Liver drug effects, Liver metabolism, Models, Molecular, Molecular Mimicry, Muscle Contraction drug effects, Muscle, Smooth, Vascular drug effects, Muscle, Smooth, Vascular physiology, Protein Structure, Secondary, Rabbits, Radioligand Assay, Rats, Receptor, Angiotensin, Type 1 metabolism, Receptor, Angiotensin, Type 2 metabolism, Swine, Uterus drug effects, Uterus metabolism, Angiotensin II chemistry, Benzodiazepines chemical synthesis, Peptides chemistry, Receptor, Angiotensin, Type 1 agonists, Receptor, Angiotensin, Type 2 agonists
- Abstract
A benzodiazepine-based beta-turn mimetic has been designed, synthesized, and incorporated into angiotensin II. Comparison of the mimetic with beta-turns in crystallized proteins showed that it most closely resembles a type II beta-turn. The compounds exhibited high to moderate binding affinity for the AT2 receptor, and one also displayed high affinity for the AT1 receptor. Molecular modeling showed that the high-affinity compounds could be incorporated into a previously derived model of AT2 receptor ligands.
- Published
- 2006
- Full Text
- View/download PDF
166. Short pseudopeptides containing turn scaffolds with high AT2 receptor affinity.
- Author
-
Georgsson J, Rosenström U, Wallinder C, Beaudry H, Plouffe B, Lindeberg G, Botros M, Nyberg F, Karlén A, Gallo-Payet N, and Hallberg A
- Subjects
- Animals, Aorta drug effects, Aorta physiology, Dose-Response Relationship, Drug, Female, Liver metabolism, Models, Chemical, Molecular Structure, Muscle Contraction drug effects, Muscle Contraction physiology, Myometrium metabolism, Protein Binding, Rabbits, Rats, Receptor, Angiotensin, Type 1 chemistry, Receptor, Angiotensin, Type 1 metabolism, Swine, Peptides chemistry, Peptides metabolism, Receptor, Angiotensin, Type 2 metabolism
- Abstract
Two pentapeptides, Ac-Tyr-Ile-His-Pro-Phe/Ile, were synthesized and shown to have angiotensin II AT2 receptor affinity and agonistic activity. Based on these peptides, a new series of 13 pseudopeptides was synthesized via introduction of five different turn scaffolds replacing the Tyr-Ile amino acid residues. Pharmacological evaluation disclosed subnanomolar affinities for some of these compounds at the AT2 receptor. Substitution of Phe by Ile in this series of ligands enhanced the AT2 receptor affinity of all compounds. These results suggest that the C-terminal amino acid residues can be elaborated on to enhance the AT2 receptor affinity in truncated Ang II analogues.
- Published
- 2006
- Full Text
- View/download PDF
167. Endomorphin-1 and endomorphin-2 differentially interact with specific binding sites for substance P (SP) aminoterminal SP1-7 in the rat spinal cord.
- Author
-
Botros M, Hallberg M, Johansson T, Zhou Q, Lindeberg G, Frändberg PA, Tömböly C, Tóth G, Le Grevès P, and Nyberg F
- Subjects
- Animals, Binding Sites, Cell Line, Tumor, Male, Protein Binding, Rats, Rats, Sprague-Dawley, Neurotransmitter Agents metabolism, Oligopeptides metabolism, Peptide Fragments chemistry, Peptide Fragments metabolism, Spinal Cord cytology, Spinal Cord metabolism, Substance P chemistry, Substance P metabolism
- Abstract
Endomorphin-1 (EM-1) and endomorphin-2 (EM-2) represent two opioid active tetrapeptides with high affinity and selectivity for the mu-opioid (MOP) receptor. Both EM-1 and EM-2 exhibit strong inhibition of pain signals in the central nervous system (CNS). In contrast to these compounds, the undecapeptide substance P (SP) facilitates pain influx in the CNS. SP has been implicated in a number of functions in the central nervous system, including pain processing and reward. Its aminoterminal fragment SP1-7 has been shown to modulate several actions of SP in the CNS, the nociceptive effect included. Although the actions of SP1-7 have been known for long no specific receptor for the SP fragment has yet been cloned. In this study, we demonstrate the presence of specific binding sites for the heptapeptide in the rat spinal cord. The binding affinity for unlabeled SP1-7 to the specific sites for the labeled heptapeptide highly exceeded those of SP and other C- or N-terminal fragments thereof. The NK-1, NK-2 and NK-3 receptor ligands [Sar9, Met(O2)11]SP, R396 and senktide, respectively, showed no or negligible binding. Moreover, both EM-1 and EM-2 were found to interact with SP1-7 binding. However, a significant difference in binding affinity between the two opioid active tetrapeptides was observed. As recorded from replacement curves the affinity of EM-2 was 10 times weaker than that for SP1-7 but about 100 times higher than that of EM-1. Among other Tyr-Pro-containing peptides Tyr-MIF-1 but not Tyr-W-MIF-1 exhibited affinity of similar potency as EM-2. These results strengthen the previously observed differences between EM-1 and EM-2 in various functional studies. Moreover, using a cell line (C6) expressing the MOP receptor it was shown that the labeled SP1-7 did not interact with binding to this receptor and no functional response was seen for the SP heptapeptide on the MOP receptor by means of stimulation in the GTPgammaS assay. This suggests that the identified SP1-7 binding sites, with high affinity also for EM-2, are not identical to the MOP receptor and apparently not to any of the known tachykinin receptors.
- Published
- 2006
- Full Text
- View/download PDF
168. New selective AT2 receptor ligands encompassing a gamma-turn mimetic replacing the amino acid residues 4-5 of angiotensin II act as agonists.
- Author
-
Rosenström U, Sköld C, Plouffe B, Beaudry H, Lindeberg G, Botros M, Nyberg F, Wolf G, Karlén A, Gallo-Payet N, and Hallberg A
- Subjects
- Amino Acid Substitution, Angiotensin II Type 2 Receptor Blockers, Animals, Benzodiazepines chemistry, Benzodiazepines pharmacology, Cell Line, Tumor, Cell Proliferation drug effects, Enzyme Activation, Female, Imidazoles pharmacology, In Vitro Techniques, Ligands, Liver drug effects, Liver metabolism, Mitogen-Activated Protein Kinase 1 metabolism, Mitogen-Activated Protein Kinase 3 metabolism, Models, Molecular, Molecular Mimicry, Myometrium drug effects, Myometrium metabolism, Neurites drug effects, Neurites physiology, Protein Conformation, Pyridines pharmacology, Radioligand Assay, Rats, Receptor, Angiotensin, Type 1 metabolism, Receptor, Angiotensin, Type 2 chemistry, Swine, Angiotensin II chemistry, Benzodiazepines chemical synthesis, Receptor, Angiotensin, Type 2 agonists
- Abstract
New benzodiazepine-based gamma-turn mimetics with one or two amino acid side chains were synthesized. The gamma-turn mimetics were incorporated into angiotensin II (Ang II) replacing the Val(3)-Tyr(4)-Ile(5) or Tyr(4)-Ile(5) peptide segments. All of the resulting pseudopeptides displayed high AT(2)/AT(1) receptor selectivity and exhibited AT(2) receptor affinity in the low nanomolar range. Molecular modeling was used to investigate whether the compounds binding to the AT(2) receptor could position important structural elements in common areas. A previously described benzodiazepine-based gamma-turn mimetic with high affinity for the AT(2) receptor was also included in the modeling. It was found that the molecules, although being structurally quite different, could adopt the same binding mode/interaction pattern in agreement with the model hypothesis. The pseudopeptides selected for agonist studies were shown to act as AT(2) receptor agonists being able to induce outgrowth of neurite cells, stimulate p42/p44(mapk), and suppress proliferation of PC12 cells.
- Published
- 2005
- Full Text
- View/download PDF
169. A selective AT2 receptor ligand with a gamma-turn-like mimetic replacing the amino acid residues 4-5 of angiotensin II.
- Author
-
Rosenström U, Sköld C, Lindeberg G, Botros M, Nyberg F, Karlén A, and Hallberg A
- Subjects
- Angiotensin II chemical synthesis, Angiotensin II pharmacology, Animals, Benzodiazepines pharmacology, Binding, Competitive, Female, Imidazoles pharmacology, In Vitro Techniques, Ligands, Liver metabolism, Membranes, Models, Molecular, Molecular Conformation, Molecular Mimicry, Myometrium metabolism, Radioligand Assay, Rats, Structure-Activity Relationship, Swine, Angiotensin II analogs & derivatives, Benzodiazepines chemical synthesis, Imidazoles chemical synthesis, Receptor, Angiotensin, Type 2 metabolism
- Abstract
Three angiotensin II (Ang II) analogues encompassing a benzodiazepine-based gamma-turn-like scaffold have been synthesized. Evaluation of the compounds in a radioligand binding assay showed that they had no affinity to the rat liver AT(1) receptor. However, one of the compounds displayed considerable affinity to the pig uterus AT(2) receptor (K(i) = 3.0 nM) while the other two lacked affinity to this receptor. It was hypothesized that the reason for the inactivity of one of these analogues to the AT(2) receptor was that the guanidino group of the Arg(2) residue and/or the N-terminal end of the pseudopeptide could not interact optimally with the receptor. To investigate this hypothesis, a conformational analysis was performed and a comparison was carried out with the monocyclic methylenedithioether analogue cyclo(S-CH(2)-S)[Cys(3,5)]Ang II which is known to bind with high affinity to the AT(2) receptor (K(i) = 0.62 nM). This comparison showed that, in the compounds with high AT(2) receptor affinity, the guanidino group of the Arg(2) residue and the N-terminal end could access common regions of space that were not accessible to the inactive compound. To examine the importance of the guanidino group for binding, the Arg side chain was removed by substituting Arg(2) for Ala(2) in the analogue having the high affinity. This analogue lacked affinity to AT(2) receptors, which supports the role of the guanidino group in receptor binding.
- Published
- 2004
- Full Text
- View/download PDF
170. Epidemiologic study of type II diabetes associated vascular complications.
- Author
-
Radwan M, Massoud AA, Botros M, and Ali MA
- Subjects
- Egypt, Female, Humans, Male, Pregnancy, Pregnancy in Diabetics epidemiology, Diabetes Mellitus, Type 2 epidemiology, Diabetic Angiopathies epidemiology
- Published
- 1987
171. [3H]acetylcholine nicotinic recognition sites in human brain: characterization of agonist binding.
- Author
-
Adem A, Synnergren B, Botros M, Ohman B, Winblad B, and Nordberg A
- Subjects
- Acetylcholine metabolism, Aged, Alkaloids metabolism, Animals, Azocines, Binding Sites, Carbachol metabolism, Humans, Male, Middle Aged, Nicotine metabolism, Quinolizines, Rats, Rats, Inbred Strains, Thalamus metabolism, Brain metabolism, Receptors, Nicotinic metabolism
- Abstract
In the presence of a cholinesterase inhibitor to prevent hydrolysis and atropine to block muscarinic cholinergic receptors, [3H]acetylcholine ([3H]ACh) binding to human brain membranes showed highest levels of nicotinic binding sites in the thalamus. [3H]ACh, in the presence of atropine, binds to heterogeneous high-affinity binding sites in human thalamus. Scatchard analysis of the binding gave a Kd of 0.58 nM and a Bmax of 3.3 pmol/g protein for the 'super high-affinity' site and a Kd of 27 nM and a Bmax of 70 pmol/g protein for the 'high-affinity' site. Moreover, in competition studies nicotinic agonists such (-)-nicotine and carbachol displaceable [3H]ACh-specific binding sites consist of both a high- and a low-affinity population of sites. These results indicate that highest levels of [3H]ACh binding in human brain were found in the thalamus. Moreover, the human thalamus was found to have multiple high-affinity nicotinic agonist sites.
- Published
- 1987
- Full Text
- View/download PDF
172. Skin glucose tests for screening diabetes mellitus.
- Author
-
Botros M
- Subjects
- Humans, Diabetes Mellitus diagnosis, Glucose analysis, Glucose Tolerance Test, Skin analysis
- Published
- 1966
173. EFFECT OF DRUGS GIVEN DURING PREGNANCY ON THE FOETUS AND NEWBORN.
- Author
-
BOTROS M
- Subjects
- Humans, Infant, Newborn, Pregnancy, Abnormalities, Drug-Induced, Drug Therapy, Fetus, Infant, Newborn, Diseases, Toxicology
- Published
- 1964
174. POSSIBLE MECHANISM OF ACTION OF 5-HYDROXYTRYPTAMINE IN INTERRUPTION OF PREGNANCY.
- Author
-
FAHIM I and BOTROS M
- Subjects
- Female, Humans, Pregnancy, Rabbits, Rats, Abortion, Induced, Castration, Fetus, Hemorrhage, Metabolism, Ovary, Physiology, Placenta, Pregnancy, Animal, Research, Serotonin, Toxicology, Uterus
- Published
- 1964
175. The glycemic effects of serotonin (5-hydroxytryptamine).
- Author
-
Botros M and Saba JA
- Subjects
- Adrenal Glands physiology, Animals, Glucose Tolerance Test, Hyperglycemia chemically induced, Injections, Intravenous, Rabbits, Blood Glucose metabolism, Serotonin pharmacology
- Published
- 1968
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.